Actinium Pharmaceuticals, Inc. (ATNM)
1.57
+0.19
(+13.77%)
USD |
NYAM |
Oct 22, 15:30
Actinium Pharmaceuticals Net Income (Quarterly) : 27.90M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 27.90M |
| March 31, 2026 | -5.522M |
| December 31, 2025 | -5.94M |
| September 30, 2025 | -5.131M |
| June 30, 2025 | -6.878M |
| March 31, 2025 | -15.94M |
| December 31, 2024 | -6.652M |
| September 30, 2024 | -11.57M |
| June 30, 2024 | -11.35M |
| March 31, 2024 | -8.67M |
| December 31, 2023 | -9.324M |
| September 30, 2023 | -13.28M |
| June 30, 2023 | -15.18M |
| March 31, 2023 | -11.04M |
| December 31, 2022 | -10.65M |
| September 30, 2022 | -9.474M |
| June 30, 2022 | -7.767M |
| March 31, 2022 | -5.129M |
| December 31, 2021 | -8.01M |
| September 30, 2021 | -6.423M |
| June 30, 2021 | -5.021M |
| March 31, 2021 | -5.32M |
| December 31, 2020 | -6.38M |
| September 30, 2020 | -5.54M |
| June 30, 2020 | -4.625M |
| Date | Value |
|---|---|
| March 31, 2020 | -5.67M |
| December 31, 2019 | -4.602M |
| September 30, 2019 | -6.599M |
| June 30, 2019 | -5.027M |
| March 31, 2019 | -5.670M |
| December 31, 2018 | -6.320M |
| September 30, 2018 | -6.148M |
| June 30, 2018 | -4.863M |
| March 31, 2018 | -6.323M |
| December 31, 2017 | -5.163M |
| September 30, 2017 | -6.323M |
| June 30, 2017 | -7.054M |
| March 31, 2017 | -8.062M |
| December 31, 2016 | -6.696M |
| September 30, 2016 | -6.599M |
| June 30, 2016 | -6.624M |
| March 31, 2016 | -4.403M |
| December 31, 2015 | -6.540M |
| September 30, 2015 | -3.946M |
| June 30, 2015 | -7.464M |
| March 31, 2015 | -3.075M |
| December 31, 2014 | -5.426M |
| September 30, 2014 | -6.077M |
| June 30, 2014 | 3.515M |
| March 31, 2014 | -16.70M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 35.00M |
| Total Expenses (Quarterly) | 7.099M |
| EPS Diluted (Quarterly) | 0.8884 |
| Enterprise Value | 8.257M |
| Gross Profit Margin (Quarterly) | 98.77% |
| Profit Margin (Quarterly) | 79.72% |
| Earnings Yield | 22.72% |
| Operating Earnings Yield | 19.47% |
| Normalized Earnings Yield | 22.72 |